Targeting CyclinD1-CDK6 to Mitigate Senescence-Driven Inflammation and Age-Associated Functional Decline
Rajesh, A.; Havas, A. P.; Arnold, R.; Lande, K.; Evensen, K. G.; Li, K. Y.; Mamde, S.; Yang, Q.; Gandhi, A.; Miller, K. N.; Teneche, M. G.; Yao, Z.; Proulx, J.; Davis, A.; Haddadin, L.; Alcaraz, M.; Macip, C. C.; Li, B.; Lei, X.; Miciano, C.; Smoot, E.; Wang, A.; Albrecht, J. H.; Williams, A. E.; Ren, B.; Yip, K. Y.; Adams, P. D.
Show abstract
Cellular senescence contributes to aging and age-related diseases by driving chronic inflammation through the Senescence Associated Secretory Phenotype (SASP) and interferon-stimulated genes (ISGs). Cyclin D1 (CCND1), a key cell cycle regulator, is paradoxically upregulated in these non-proliferating cells. We show that CCND1 and its kinase partner CDK6 drive SASP and ISG expression in senescent cells by promoting DNA damage accumulation. This leads to the formation of cytoplasmic chromatin fragments (CCFs) that activate pro-inflammatory CGAS-STING signaling. The tumor suppressor p53 (TP53) and its target p21 (CDKN2A) antagonize this CCND1-CDK6-dependent DNA damage accumulation pathway to suppress the SASP. In aged mouse livers, senescent hepatocytes show increased Ccnd1 expression. Hepatocyte-specific Ccnd1 knockout or treatment with the Cdk4/6 inhibitor Palbociclib reduces DNA damage and ISGs in aged mouse liver. Notably, Palbociclib also suppresses frailty and improves physical performance of aged mice. These findings reveal a novel role for CCND1/CDK6 in regulating DNA damage and inflammation in senescence and aging, highlighting it as a promising therapeutic target.
Matching journals
The top 4 journals account for 50% of the predicted probability mass.